Business Segment and Geographical Information (Tables)
|
12 Months Ended |
Dec. 31, 2017 |
Segment Reporting [Abstract] |
|
Schedule of Segment Reporting Information, by Segment [Table Text Block] |
Business Segment Information | | | | | | | | | | | | | | (In millions) | | 2017 |
| | 2016 |
| | 2015 |
| | | | | | | | Revenues | | | | | | | Life Sciences Solutions | | $ | 5,728 |
| | $ | 5,317 |
| | $ | 4,774 |
| Analytical Instruments | | 4,821 |
| | 3,668 |
| | 3,208 |
| Specialty Diagnostics | | 3,486 |
| | 3,339 |
| | 3,244 |
| Laboratory Products and Services | | 7,825 |
| | 6,724 |
| | 6,372 |
| Eliminations | | (942 | ) | | (774 | ) | | (633 | ) | | | | | | | | Consolidated revenues | | 20,918 |
| | 18,274 |
| | 16,965 |
| | | | | | | | Segment Income (a) | | | | | | | Life Sciences Solutions | | 1,896 |
| | 1,596 |
| | 1,414 |
| Analytical Instruments | | 1,027 |
| | 745 |
| | 613 |
| Specialty Diagnostics | | 930 |
| | 910 |
| | 873 |
| Laboratory Products and Services | | 1,007 |
| | 971 |
| | 922 |
| | | | | | | | Subtotal reportable segments (a) | | 4,860 |
| | 4,222 |
| | 3,822 |
| | | | | | | | Cost of revenues charges | | (123 | ) | | (102 | ) | | (9 | ) | Selling, general and administrative charges, net | | (78 | ) | | (104 | ) | | (46 | ) | Restructuring and other costs, net | | (97 | ) | | (189 | ) | | (116 | ) | Amortization of acquisition-related intangible assets | | (1,594 | ) | | (1,378 | ) | | (1,315 | ) | | | | | | | | Consolidated operating income | | 2,968 |
| | 2,449 |
| | 2,336 |
| Other expense, net (b) | | (539 | ) | | (425 | ) | | (400 | ) | | | | | | | | Income from continuing operations before income taxes | | $ | 2,429 |
| | $ | 2,024 |
| | $ | 1,936 |
| | | | | | | | Depreciation | | | | | | | Life Sciences Solutions | | $ | 129 |
| | $ | 142 |
| | $ | 147 |
| Analytical Instruments | | 71 |
| | 50 |
| | 39 |
| Specialty Diagnostics | | 72 |
| | 70 |
| | 74 |
| Laboratory Products and Services | | 167 |
| | 118 |
| | 113 |
| | | | | | | | Consolidated depreciation | | $ | 439 |
| | $ | 380 |
| | $ | 373 |
|
| | (a) | Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles. |
| | (b) | The company does not allocate other expense, net to its segments. |
| | | | | | | | | | | | | | (In millions) | | 2017 |
| | 2016 |
| | 2015 |
| | | | | | | | Total Assets | | | | | | | Life Sciences Solutions | | $ | 19,063 |
| | $ | 19,065 |
| | $ | 18,537 |
| Analytical Instruments | | 9,960 |
| | 9,520 |
| | 4,763 |
| Specialty Diagnostics | | 7,095 |
| | 6,802 |
| | 7,183 |
| Laboratory Products and Services | | 19,181 |
| | 9,405 |
| | 9,614 |
| Corporate/Other (c) | | 1,370 |
| | 1,116 |
| | 737 |
| | | | | | | | Consolidated total assets | | $ | 56,669 |
| | $ | 45,908 |
| | $ | 40,834 |
| | | | | | | | Capital Expenditures | | | | | | | Life Sciences Solutions | | $ | 118 |
| | $ | 122 |
| | $ | 93 |
| Analytical Instruments | | 56 |
| | 34 |
| | 60 |
| Specialty Diagnostics | | 87 |
| | 72 |
| | 76 |
| Laboratory Products and Services | | 178 |
| | 111 |
| | 90 |
| Corporate/Other | | 69 |
| | 105 |
| | 104 |
| | | | | | | | Consolidated capital expenditures | | $ | 508 |
| | $ | 444 |
| | $ | 423 |
|
| | (c) | Corporate assets consist primarily of cash and cash equivalents, short-term investments, property and equipment at the company's corporate offices. |
|
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] |
Business Segment Information | | | | | | | | | | | | | | (In millions) | | 2017 |
| | 2016 |
| | 2015 |
| | | | | | | | Revenues | | | | | | | Life Sciences Solutions | | $ | 5,728 |
| | $ | 5,317 |
| | $ | 4,774 |
| Analytical Instruments | | 4,821 |
| | 3,668 |
| | 3,208 |
| Specialty Diagnostics | | 3,486 |
| | 3,339 |
| | 3,244 |
| Laboratory Products and Services | | 7,825 |
| | 6,724 |
| | 6,372 |
| Eliminations | | (942 | ) | | (774 | ) | | (633 | ) | | | | | | | | Consolidated revenues | | 20,918 |
| | 18,274 |
| | 16,965 |
| | | | | | | | Segment Income (a) | | | | | | | Life Sciences Solutions | | 1,896 |
| | 1,596 |
| | 1,414 |
| Analytical Instruments | | 1,027 |
| | 745 |
| | 613 |
| Specialty Diagnostics | | 930 |
| | 910 |
| | 873 |
| Laboratory Products and Services | | 1,007 |
| | 971 |
| | 922 |
| | | | | | | | Subtotal reportable segments (a) | | 4,860 |
| | 4,222 |
| | 3,822 |
| | | | | | | | Cost of revenues charges | | (123 | ) | | (102 | ) | | (9 | ) | Selling, general and administrative charges, net | | (78 | ) | | (104 | ) | | (46 | ) | Restructuring and other costs, net | | (97 | ) | | (189 | ) | | (116 | ) | Amortization of acquisition-related intangible assets | | (1,594 | ) | | (1,378 | ) | | (1,315 | ) | | | | | | | | Consolidated operating income | | 2,968 |
| | 2,449 |
| | 2,336 |
| Other expense, net (b) | | (539 | ) | | (425 | ) | | (400 | ) | | | | | | | | Income from continuing operations before income taxes | | $ | 2,429 |
| | $ | 2,024 |
| | $ | 1,936 |
| | | | | | | | Depreciation | | | | | | | Life Sciences Solutions | | $ | 129 |
| | $ | 142 |
| | $ | 147 |
| Analytical Instruments | | 71 |
| | 50 |
| | 39 |
| Specialty Diagnostics | | 72 |
| | 70 |
| | 74 |
| Laboratory Products and Services | | 167 |
| | 118 |
| | 113 |
| | | | | | | | Consolidated depreciation | | $ | 439 |
| | $ | 380 |
| | $ | 373 |
|
| | (a) | Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles. |
| | (b) | The company does not allocate other expense, net to its segments. |
|
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] |
Geographical Information | | | | | | | | | | | | | | (In millions) | | 2017 |
| | 2016 |
| | 2015 |
| | | | | | | | Revenues (d) | | | | | | | United States | | $ | 10,177 |
| | $ | 9,086 |
| | $ | 8,607 |
| China | | 2,058 |
| | 1,730 |
| | 1,376 |
| Other | | 8,683 |
| | 7,458 |
| | 6,982 |
| | | | | | | | Consolidated revenues | | $ | 20,918 |
| | $ | 18,274 |
| | $ | 16,965 |
| | | | | | | | Long-lived Assets (e) | | | | | | | United States | | $ | 2,349 |
| | $ | 1,630 |
| | $ | 1,532 |
| United Kingdom | | 277 |
| | 217 |
| | 261 |
| Other | | 1,421 |
| | 731 |
| | 656 |
| | | | | | | | Consolidated long-lived assets | | $ | 4,047 |
| | $ | 2,578 |
| | $ | 2,449 |
|
| | (d) | Revenues are attributed to countries based on customer location. |
| | (e) | Includes property, plant and equipment, net |
|